NA
HRTX icon

Neuburgh Advisers’s Heron Therapeutics HRTX Stock Holding History

Neuburgh Advisers’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$13K Hold
688
– – ﹤0.01% 901
2019
Q2 		$13K Buy
+688
New +$13.7K ﹤0.01% 895

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Neuburgh Advisers's HRTX Position: Q3 2019 in Review

Neuburgh Advisers held its Heron Therapeutics (HRTX) position steady in Q3 2019 at 688 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #901.

Neuburgh Advisers first reported a position in HRTX in Q2 2019 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold HRTX as of Q3 2019.

  • Neuburgh Advisers held 688 shares of Heron Therapeutics worth $13K as of Q3 2019.
  • Neuburgh Advisers left its Heron Therapeutics share count unchanged in Q3 2019.
  • Heron Therapeutics made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #901 holding.
  • Neuburgh Advisers first reported a position in Heron Therapeutics in Q2 2019 and has held it in 2 quarters since.
  • 180 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.